Resistance to paclitaxel in hepatoma cells is related to static JNK activation and prohibition into entry of mitosis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 302, Issue 9, 2012, Pages

  Chae, Sunyoung ^a   Kim, Young Bae ^b   Lee, Jong Soo ^c,d   Cho, Hyeseong ^a,c  

^a Ajou University School of Medicine   (South Korea)

^b Ajou Good Hospital   (South Korea)

^c Departments of Molecular Science Technology   (South Korea)

^d Ajou University   (South Korea)

Author keywords

Bcl 2; G2 M transition; Hepatocellular carcinoma

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CAFFEINE; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; PACLITAXEL; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; ENZYME ACTIVITY; G2 PHASE CELL CYCLE CHECKPOINT; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; LIVER NEOPLASMS; MAP KINASE KINASE 4; MITOSIS; PACLITAXEL; TREATMENT OUTCOME;

EID: 84860516137     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00449.2011     Document Type: Article

References (50)

1. Ashwell S, Zabludoff S. DNA damage detection and repair pathways- recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 14: 4032-4037, 2008.
2. Asnaghi L, Calastretti A, Bevilacqua A, D'Agnano I, Gatti G, Canti G, Delia D, Capaccioli S, Nicolin A. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene 23: 5781-5791, 2004.
3. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20: 147-155, 2001.
4. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Ørntoft T, Lukas J, Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870, 2005.
5. Blagosklonny MV. Unwinding the loop of Bcl-2 phosphorylation. Leukemia 15: 869-874, 2001.
6. Blagosklonny MV, Bishop PC, Robey R, Fojo T, Bates SE. Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells. Cancer Res 60: 3425-3428, 2000.
7. Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment with DNAdamaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 105: 533-539, 2000.
8. Burlacu A. Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med 7: 249-257, 2003.
9. Calastretti A, Bevilacqua A, Ceriani C, Vigano S, Zancai P, Capaccioli S, Nicolin A. Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase. Oncogene 20: 6172-6180, 2001.
10. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336: 1855-1859, 1997.
11. Cheung HW, Ling MT, Tsao SW, Wong YC, Wang X. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 25: 881-887, 2004.
12. Chun E, Lee KY. Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 315: 771-779, 2004.
13. Deng X, Xiao L, Lang W, Gao F, Ruvolo P, May WS Jr. Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem 276: 23681-23688, 2001.
14. Du L, Lyle CS, Chambers TC. Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction. Oncogene 24: 107-117, 2005.
15. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061-1070, 1999.
16. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 37, Suppl 2: S88-S94, 2007.
17. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
18. Fang G, Chang BS, Kim CN, Perkins C, Thompson CB, Bhalla KN. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res 58: 3202-3208, 1998.
19. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687, 2006.
20. Furukawa Y, Iwase S, Kikuchi J, Terui Y, Nakamura M, Yamada H, Kano Y, Matsuda M. Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation. J Biol Chem 275: 21661-21667, 2000.
21. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913, 2005.
22. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
23. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
24. Hoeijmakers JH. DNA damage, aging, cancer. N Engl J Med 361: 1475-1485, 2009.
25. Jin C, Li H, He Y, He M, Bai L, Cao Y, Song W, Dou K. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J Cancer Res Clin Oncol 136: 267-274, 2010.
26. Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14: 95-100, 2009.
27. Ku JL, Park JG. Biology of SNU cell lines. Cancer Res Treat 37: 1-19, 2005.
28. Kudo M. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. Dig Dis 29: 273-277, 2011.
29. Kutuk O, Letai A. Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death Differ 17: 1624-1635, 2010.
30. Liu ZG, Baskaran R, Lea-Chou ET, Wood LD, Chen Y, Karin M, Wang JY. Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature 384: 273-276, 1996.
31. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442, 2003.
32. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327, 2008.
33. Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C, Gillieron C, Boschert U, Vial-Knecht E, Martinou JC, Arkinstall S. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem 272: 25238-25242, 1997.
34. Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, Van Den Berg CL. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 23: 596-604, 2004.
35. Park JG, Lee JH, Kang MS, Park KJ, Jeon YM, Lee HJ, Kwon HS, Park HS, Yeo KS, Lee KU. Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer 62: 276-282, 1995.
36. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
37. Pearce AK, Humphrey TC. Integrating stress-response and cell-cycle checkpoint pathways. Trends Cell Biol 11: 426-433, 2001.
38. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 332: 1004-1014, 1995.
39. Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 15: 515-522, 2001.
40. Sherman M. Recurrence of hepatocellular carcinoma. N Engl J Med 359: 2045-2047, 2008.
41. Shin HM, Han TH. CD28-mediated regulation of the c-jun promoter involves the MEF2 transcription factor in Jurkat T cells. Mol Immunol 36: 197-203, 1999.
42. Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 96: 3775-3780, 1999.
43. Tanaka S, Shimada M, Shirabe K, Maehara S, Tsujita E, Taketomi A, Maehara Y. Surgical outcome of patients with hepatocellular carcinoma originating in the caudate lobe. Am J Surg 190: 451-455, 2005.
44. Teraishi F, Wu S, Sasaki J, Zhang L, Davis JJ, Guo W, Dong F, Fang B. JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells. Cell Mol Life Sci 62: 2382-2389, 2005.
45. Teraishi F, Wu S, Zhang L, Guo W, Davis JJ, Dong F, Fang B. Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells. Cancer Res 65: 6380-6387, 2005.
46. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23: 8093-8108, 2005.
47. Wang Q, Wieder R. All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene 23: 426-433, 2004.
48. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88: 2619-2628, 2000.
49. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, Belmont LD, Kaminker JS, O'Rourke KM, Pujara K, Kohli PB, Johnson AR, Chiu ML, Lill JR, Jackson PK, Fairbrother WJ, Seshagiri S, Ludlam MJ, Leong KG, Dueber EC, Maecker H, Huang DC, Dixit VM. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471: 110-114, 2011.
50. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19: 8469-8478, 1999.